Neotigason (Acitretin)

Acitretin, the active ingredient in Neotigason, is a retinoid presented as a capsule for oral use. It treats severe plaque psoriasis, pustular psoriasis, ichthyosis and other disorders of keratinization in adult patients, and is indicated when topical therapies are insufficient. GNH USA supplies Neotigason as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution, offering consistent batch release and regulatory compliance.

Acitretin is used to manage disorders of keratinization and severe psoriasis. - Severe plaque psoriasis: reduces scaling and erythema, improving skin appearance. - Pustular psoriasis: controls pustule formation and accelerates lesion clearance. - Ichthyosis: normalizes epidermal differentiation, decreasing hyperkeratosis. - Disorders of keratinization: modulates keratinocyte proliferation to improve skin texture.

Acitretin may cause a range of adverse reactions, varying from mild to severe. Common Side Effects: - Dry skin: increased xerosis and scaling. - Cheilitis: inflammation and cracking of the lips. - Elevated triglycerides: rise in serum lipid levels. - Hair loss: temporary alopecia. - Headache: mild to moderate intensity. Serious or Rare Side Effects: - Hepatotoxicity: liver enzyme elevations or injury. - Severe hyperlipidemia: marked increase in cholesterol or triglycerides. - Pseudotumor cerebri: increased intracranial pressure causing headaches and visual changes.

When prescribing acitretin, several precautions should be observed to minimize risks. - Pregnancy contraindication: teratogenic; avoid use in women of childbearing potential and discontinue at least 3 years before conception. - Liver function monitoring: assess baseline hepatic enzymes and repeat periodically. - Lipid profile monitoring: check serum triglycerides and cholesterol before treatment and during therapy. - Skeletal effects: avoid in children; monitor for premature epiphyseal closure in adolescents. - Concomitant vitamin A: avoid excessive vitamin A intake from supplements or diet. - Store at ambient temperature: keep capsules below 25°C in the original container, protect from moisture and light.

Acitretin can interact with several medicines, altering efficacy or safety. Major Interactions (Avoid): - Tetracyclines: increased risk of intracranial hypertension. - Vitamin A supplements: additive teratogenicity and hypervitaminosis A. - Oral retinoids (e.g., isotretinoin): cumulative toxicity, avoid concurrent use. Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin): potential enhancement of anticoagulant effect. - Lipid‑lowering agents (fibrates, statins): may exacerbate lipid abnormalities. - CYP450 inducers (e.g., rifampicin): may reduce acitretin plasma levels.